When cytarabine is combined with drugs that block PRMT5 or MAT2A, cancer cells with 9p21 loss die more effectively because these drugs together cause more DNA damage and replication problems than either drug alone.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review could determine whether combinations of cytarabine with PRMT5 or MAT2A inhibitors improve survival in patients with 9p21-loss tumors compared to standard therapy.
A systematic review and meta-analysis of all published clinical trials (n≥8) evaluating cytarabine + PRMT5/MAT2A inhibitors in patients with 9p21-loss solid tumors, with standardized genetic confirmation, primary endpoints of overall survival and progression-free survival, and subgroup analysis by tumor type.
An RCT could determine whether adding PRMT5 or MAT2A inhibitors to cytarabine improves survival in patients with 9p21-loss bladder cancer.
A multicenter, double-blind RCT of 200+ patients with advanced 9p21-loss bladder cancer randomized to cytarabine + PRMT5 inhibitor (MRTX1719) vs. cytarabine + placebo, with primary endpoint of progression-free survival at 12 months, confirmed by central genetic testing and biomarker analysis.
A prospective cohort could determine whether patients with 9p21-loss tumors treated with cytarabine + PRMT5/MAT2A inhibitors have improved outcomes compared to those receiving other combinations.
A prospective cohort study following 300+ patients with advanced 9p21-loss tumors treated with cytarabine + PRMT5 or MAT2A inhibitors, tracking response rates, toxicity, and survival over 24 months, with pre-treatment genetic and biomarker profiling.
A case-control study could compare the frequency of 9p21 loss in patients who responded to cytarabine + PRMT5 inhibitors versus those who did not.
A case-control study comparing 100 patients with advanced cancer who achieved durable response to cytarabine + PRMT5 inhibitor (≥6 months) versus 100 non-responders, matched for tumor type and prior therapy, with retrospective 9p21 deletion status assessed by NGS.
A cross-sectional analysis could correlate 9p21 loss with increased DNA damage markers in tumors treated with cytarabine + PRMT5 inhibitors.
A cross-sectional analysis of 150+ tumor biopsies from patients treated with cytarabine + PRMT5 inhibitor, measuring 9p21 deletion status and levels of γH2AX and pRPA32 via immunohistochemistry, correlating with clinical response.